Highlights

  • XRF Scientific shares rose 3.22% to AUD 1.92 on 23 April 2026 following the announcement of a business acquisition expanding its analytical instrument portfolio.
  • The company has entered a binding agreement to acquire Bruker’s Combustion Gas Analysis business for an upfront USD 4 million consideration.
  • The acquired business generated unaudited revenue of USD 5.3 million in 2025 across global markets.
  • The acquisition introduces new exposure to non-mining sectors and expands XRF’s addressable industries.
  • Production is expected to transition to Perth, with revenue contribution anticipated from Q4 2026.

XRF Scientific Limited (ASX:XRF) shares moved 3.22% higher to AUD 1.92 during the morning session on 23 April 2026, with the stock now up 22.61% over the past year. Today’s upward movement follows the company’s announcement of a binding agreement to acquire a combustion gas analysis business, signalling an expansion of its analytical instrument offering and entry into additional industry segments.

XRF Scientific Limited is an Australia-based company engaged in the manufacture and supply of equipment and chemicals used in sample preparation for analysis. The company serves production mines, construction material companies, and commercial laboratories globally, with manufacturing and support facilities across multiple regions including Australia, Europe, Canada, and India. Its customer base includes multinational industrial and resource companies, reflecting its presence in established industrial supply chains.

Acquisition Expands Analytical Instrument Portfolio

The company has entered into a binding Asset Purchase Agreement through its wholly owned subsidiary to acquire the Combustion Gas Analysis (CGA) business from Bruker AXS SE. Completion of the transaction is expected to occur imminently, with no conditions precedent attached, once the upfront consideration is received.

The CGA business comprises a range of four analytical instruments designed for elemental analysis of carbon, sulfur, oxygen, hydrogen, and nitrogen. These instruments utilise multiple technologies, including hot extraction, inert gas fusion, and combustion through induction heating, enabling precise and rapid analysis across different applications.

Under the agreement, selected product names, including “G4 Icarus,” will transfer to XRF Scientific and be rebranded under its portfolio. This addition is expected to broaden the company’s existing product offering within analytical instrumentation.

Exposure to Diverse Industrial Applications

The CGA product range is used across a wide range of industries, extending beyond mining into multiple industrial and manufacturing sectors. These include nuclear energy materials, magnetic materials such as rare earths, powder metallurgy, additive manufacturing, and welding.

The instruments are also utilised in ores and minerals processing, iron and steel production, and metal processing involving copper, aluminium, magnesium, and stainless steel. Additional applications include cement production, glass and ceramics manufacturing, and materials such as limestone and dolomite.

This diversification is expected to expand XRF’s exposure to non-mining industries, complementing its existing market presence and supporting broader industry participation.

Historical Performance Provides Revenue Base

According to unaudited management accounts provided by the vendor, the CGA business generated revenue of approximately USD 5.3 million in 2025. This revenue includes sales of instruments, spare parts, and servicing, indicating a combination of product and recurring service income.

The business operates across global markets, with sales recorded in Europe, North America, and Asia. Distribution is primarily conducted through third-party distributors, a model that XRF Scientific expects to maintain and potentially expand following the acquisition.

The company has noted that the historical financial information has not been independently verified, and investors are advised to consider associated uncertainties when assessing these figures.

Transition Plan and Production Relocation

Currently, the CGA products are manufactured in Karlsruhe, Germany. Under the agreed transition plan, production will be relocated to XRF Scientific’s facility in Perth, Australia. This process is expected to be completed during the third quarter of calendar year 2026.

During the transition period, the vendor will provide support to ensure continuity in product quality and customer service. Key sales management and technical support personnel based in Germany and the United States are expected to join XRF Scientific, supporting operational continuity and customer relationships.

Revenue from the CGA business is expected to begin contributing following the completion of the production transfer, with initial contributions anticipated from the fourth quarter of calendar year 2026.

Acquisition Structure and Consideration Details

The acquisition involves an upfront cash payment of USD 4 million, funded from XRF Scientific’s existing cash reserves. This consideration includes approximately USD 0.8 million worth of inventory and demonstration instruments, valued at cost.

In addition to the upfront payment, the agreement includes an earnout component of up to USD 1 million. This earnout is based on 7% of net revenue generated from the CGA products and services over a three-year period following completion. Payments under this arrangement will be made every six months in arrears.

This structure aligns part of the acquisition cost with future performance, linking additional payments to revenue generation over time.

Strategic Rationale and Product Synergies

The acquisition is positioned as a complementary addition to XRF Scientific’s existing product suite. The CGA instruments expand the company’s analytical capabilities, providing opportunities to cross-sell alongside existing products such as xrTGA, Labfit CS-1232, and xrFuse.

The addition of consumables required for the operation of CGA instruments also introduces potential recurring revenue streams. These consumables are necessary for ongoing use of the instruments, supporting a longer-term revenue contribution beyond initial equipment sales.

The company also noted that the acquisition provides access to new industries, particularly those outside the mining sector, supporting diversification of its revenue base.

Company Positioning and Global Reach

XRF Scientific has established a presence in multiple global markets, supported by manufacturing, sales, and distribution networks. Its products are used in industrial quality control and process optimisation, helping customers measure material composition and improve operational efficiency.

The company’s customer base includes multinational organisations across mining, metals, construction materials, and industrial sectors. Its technologies are applied in improving product quality, enhancing productivity, and reducing operational inefficiencies.

With the addition of the CGA business, XRF Scientific is expanding its analytical instrument portfolio while maintaining its focus on industrial and laboratory applications.

What This Means for Investors?

The announcement reflects a step in expanding XRF Scientific’s product offering and industry exposure through the acquisition of an established analytical instrument business. The inclusion of a revenue-generating product line with global distribution aligns with the company’s broader growth approach.

The transition plan, including the relocation of production and integration of personnel, will be a key factor in the timing of revenue contribution. Initial revenue from the acquisition is expected from the fourth quarter of calendar year 2026, following completion of the transition.

The share price movement on 23 April 2026 appears to reflect market attention toward the acquisition and its potential to contribute to the company’s operations and product diversification.